Literature DB >> 18930814

Targets for neuroprotection in Parkinson's disease.

Talene A Yacoubian1, David G Standaert.   

Abstract

Current therapies for Parkinson's disease significantly improve the quality of life for patients suffering from this neurodegenerative disease, yet none of the current therapies has been convincingly shown to slow or prevent the progression of disease. Much has been learned about the pathophysiology of Parkinson's disease in recent years, and these discoveries offer a variety of potential targets for protective therapy. Mechanisms implicated in the disease process include oxidative stress, mitochondrial dysfunction, protein aggregation and misfolding, inflammation, excitotoxicity, and apoptosis. At the same time, the involvement of these diverse processes makes modeling the disease and evaluation of potential treatments difficult. In addition, available clinical tools are limited in their ability to monitor the progression of the disease. In this review, we summarize the different pathogenic mechanisms implicated in Parkinson's disease and neuroprotective strategies targeting these mechanisms currently under clinical study or under preclinical development, with a view towards strategies that seem most promising.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930814      PMCID: PMC2740981          DOI: 10.1016/j.bbadis.2008.09.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  241 in total

1.  The non-immunosuppressive immunophilin ligand GPI-1046 potently stimulates regenerating axon growth from adult mouse dorsal root ganglia cultured in Matrigel.

Authors:  Z Khan; G Ferrari; M Kasper; D A Tonge; J P Steiner; G S Hamilton; P R Gordon-Weeks
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

2.  Maternal inheritance in Parkinson's disease.

Authors:  G F Wooten; L J Currie; J P Bennett; M B Harrison; J M Trugman; W D Parker
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

3.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.

Authors:  Y He; S Appel; W Le
Journal:  Brain Res       Date:  2001-08-03       Impact factor: 3.252

4.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

5.  The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil.

Authors:  J W Phillis
Journal:  Brain Res       Date:  1995-12-24       Impact factor: 3.252

6.  Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue.

Authors:  Angela M Bodles; Omar M A El-Agnaf; Brett Greer; David J S Guthrie; G Brent Irvine
Journal:  Neurosci Lett       Date:  2004-04-08       Impact factor: 3.046

7.  Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro.

Authors:  N Ogawa; K Tanaka; M Asanuma; M Kawai; T Masumizu; M Kohno; A Mori
Journal:  Brain Res       Date:  1994-09-19       Impact factor: 3.252

8.  Statin use and the risk of Parkinson disease.

Authors:  Angelika D Wahner; Jeff M Bronstein; Yvette M Bordelon; Beate Ritz
Journal:  Neurology       Date:  2008-01-09       Impact factor: 9.910

Review 9.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

Authors:  Penelope J Hallett; David G Standaert
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

10.  Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells.

Authors:  Wanli W Smith; Russell L Margolis; Xiaojie Li; Juan C Troncoso; Michael K Lee; Valina L Dawson; Ted M Dawson; Takashi Iwatsubo; Christopher A Ross
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.709

View more
  49 in total

1.  CSF markers of neurodegeneration in Parkinson's disease.

Authors:  Hana Přikrylová Vranová; Jan Mareš; Martin Nevrlý; David Stejskal; Jana Zapletalová; Petr Hluštík; Petr Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2010-08-21       Impact factor: 3.575

Review 2.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.

Authors:  Marika Cordaro; Rosalba Siracusa; Rosalia Crupi; Daniela Impellizzeri; Alessio Filippo Peritore; Ramona D'Amico; Enrico Gugliandolo; Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Mol Neurobiol       Date:  2018-04-14       Impact factor: 5.590

4.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

5.  The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.

Authors:  Yin-Xiu Ding; Yi Xia; Xi-Ying Jiao; Li Duan; Jun Yu; Xi Wang; Liang-Wei Chen
Journal:  Neurochem Res       Date:  2011-05-12       Impact factor: 3.996

6.  A perspective on neuronal cell death signaling and neurodegeneration.

Authors:  Scott Brady; Gerardo Morfini
Journal:  Mol Neurobiol       Date:  2010-05-18       Impact factor: 5.590

7.  Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model.

Authors:  Shireen A Hedya; Marwa M Safar; Ashraf K Bahgat
Journal:  Mol Neurobiol       Date:  2018-02-10       Impact factor: 5.590

8.  Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration.

Authors:  Anumantha Kanthasamy; Huajun Jin; Vellareddy Anantharam; Gautam Sondarva; Velusamy Rangasamy; Ajay Rana; Arthi Kanthasamy
Journal:  Neurotoxicology       Date:  2012-02-07       Impact factor: 4.294

Review 9.  Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease.

Authors:  Georgia S Gaki; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2014-02-13       Impact factor: 3.843

10.  Potential molecular mechanisms mediating the protective effects of tetrahydroxystilbene glucoside on MPP+-induced PC12 cell apoptosis.

Authors:  Lingling Zhang; Linhong Huang; Xiaobing Li; Cuicui Liu; Xin Sun; Leitao Wu; Tao Li; Hao Yang; Jianzong Chen
Journal:  Mol Cell Biochem       Date:  2017-08-29       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.